globenewswire.com · 26 jun
Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap®
COPENHAGEN, Denmark, June 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company has been added to the broad-market Russell 3000® Index, the large-cap Russell 1000® Index, the small-to-mid-cap Russell 2500® Index, and the Russell Midcap® Index as a part of the 2026 Russell U.S. Indexes semi-annual reconstitution, effective at the close of U.S. equity markets on June 26, 2026.
globenewswire.com · 25 jun
Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026
COPENHAGEN, Denmark, June 25, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest data from its clinical development programs for the treatment of children with achondroplasia will be shared in an oral presentation and two posters at ICCBH 2026, the 12th International Conference on Children's Bone Health being held in Montreal from June 27-30. The data include an oral presentation of Week 104 data showing improvements in lower-extremity alignment from the recently completed pivotal ApproaCH Trial of TransCon® CNP (navepegritide) by Leanne Ward, M.D., Professor of Pediatrics in the Faculty of Medicine at the University of Ottawa (Canada), as well as a late-breaking poster of radiographic and anthropometric data from Week 52 of the COACH Trial of combination therapy with TransCon CNP and TransCon hGH (lonapegsomatropin).
globenewswire.com · 13 jun
Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism
COPENHAGEN, Denmark, June 13, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced Week 182 data from its completed Phase 3 PaTHway Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) demonstrated sustained efficacy and safety in adults with hypoparathyroidism. Over the three-and-a-half-year duration of the trial, TransCon PTH replicated the systemic actions of endogenous PTH, with a balanced, beneficial impact on the main target organ systems – CNS, kidney, small intestine, and bone – as demonstrated by improved quality of life and normalized and stable urine calcium, serum calcium, serum phosphate, and bone mineral density. These benefits were sustained while enabling independence from conventional therapy with active vitamin D and calcium.
seekingalpha.com · 12 jun
Touchstone Mid Cap Growth Fund Q1 2026 Portfolio Review
The Touchstone Mid Cap Growth Fund (Class A Shares, Load Waived) outperformed its benchmark, the Russell Midcap Growth Index, for the quarter ended March 31, 2026. Among the top contributors to relative performance during the quarter were Vertiv Holdings, Ascendis Pharma, Howmet Aerospace, Diamondback Energy, and Roblox Corp. The largest detractors from relative performance during the quarter were Atlassian Corp., DoorDash Inc., Ares Management, Axon Enterprise, and MongoDB.
globenewswire.com · 11 jun
5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism
– Multi-organ system and quality-of-life benefits sustained through five years of treatment – 82% response rate for the multi-component endpoint – 95% of patients completed five years of treatment COPENHAGEN, Denmark, June 11, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced 5-year (Week 266) data from its Phase 2 PaTH Forward Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) demonstrated sustained efficacy and safety in adults with hypoparathyroidism. Over the five-year duration of the trial, TransCon PTH replicated the systemic actions of endogenous PTH, with a balanced, beneficial impact on the main target organ systems – kidney, small intestine, CNS, and bone – as demonstrated by normalized and stable urine calcium, serum calcium, quality of life, and bone mineral density.
globenewswire.com · 8 jun
Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026
COPENHAGEN, Denmark, June 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest data from its Endocrinology Rare Disease programs in hypoparathyroidism, achondroplasia, and pediatric growth hormone deficiency will be shared in two oral presentations and three posters at ENDO 2026, the annual meeting of the Endocrine Society being held in Chicago from June 13-16, 2026.
seekingalpha.com · 28 may
Ascendis Pharma: Rare Endocrine Compounder Entering Growth Phase (Initiating Buy)
Ascendis Pharma is initiated with a buy rating, reflecting its transition to a durable, commercial-stage rare endocrine franchise. ASND's valuation premium is justified by high-quality revenue growth, multiple product launches, operating leverage, and reduced financing risk. Yorvipath and Yuviwel are driving robust pipeline momentum, with Yorvipath scaling rapidly in chronic hypoparathyroidism and Yuviwel poised for expansion in achondroplasia.